Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00675701 · ClinicalTrials.gov registry record · Phase 1
A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study
A Phase 1 study, sponsored by CardioKine.
- Completed
- Registry status
- Phase 1
- Development phase
- 298
- Enrollment target
NCT00675701 is a Phase 1 study that has completed, run by CardioKine. The registered enrollment target is 298 participants.
The verdict
NCT00675701, a Phase 1 study, has completed, sponsored by CardioKine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 298 participants
- Enrollment target
Study Summary
This is a Phase 1, double-blind, randomized, repeat-dose, single -dite, 4-arm parallel group study to define the ECG effect of lixivaptan using a therapeutic and supratherapeutic dose compared to placebo and moxifloxacin (a positive control in healthy adult men and women.
Interventions
- DRUG placebo
- DRUG moxifloxacin
- DRUG lixivaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00675701
The ClinicalTrials.gov registry entry for NCT00675701 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CardioKine, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00675701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00675701 about?
NCT00675701 is a clinical study titled "A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study". This is a Phase 1, double-blind, randomized, repeat-dose, single -dite, 4-arm parallel group study to define the ECG effect of lixivaptan using a therapeutic and supratherapeutic dose compared to placebo and moxifloxacin (a positive control in healthy adult men and women.
What is the current status of trial NCT00675701?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 298 participants. The study started on 2008-05. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00675701?
The interventions under investigation include: placebo (DRUG), moxifloxacin (DRUG), lixivaptan (DRUG).
Who is sponsoring clinical trial NCT00675701?
This trial is sponsored by CardioKine, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.